Partnerships, Licensing, Investments and M&A Deals and Trends for June 2021 in Pharmaceuticals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends for June 2021 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in June 2021. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women’s health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary, 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, June 2021 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, June2021 12

2.2.1 Blackstone, Carlyle and Hellman & Friedman to Invest in Medline Industries 12

2.2.2 Danaher to Acquire Aldevron 13

2.2.3 Bausch Health Prices USD1.6 Billion in Private Placement of

4.875% Senior Secured Notes Due 2028 13

2.2.4 Eisai Enters into Agreement with Bristol Myers Squibb 13

2.2.5 Kite Pharma Enters into Co-Development Agreement with Shoreline Biosciences 14

2.2.6 Bristol Myers Squibb Exercises License Option from Prothena 14

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, June 2021 15

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, June 2021 16

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, June 2021 17

3.1.1 Top M&A Deals in June 2021 18

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, January 2021– June 2021 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, June 2021 20

3.2.1 Top Equity Offering Deals in June 2021 21

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, January 2021 – June 2021 22

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, June 2021 23

3.3.1 Top PE/VC Deals in June 2021 24

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, June 2021 25

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, June 2021 26

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, January 2021 – June 2021 27

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, January 2021–June 2021 28

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, June 2021 29

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, January 2021 – June 2021 30

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), June 2021 32

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, June 2021 33

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2021 – June 2021 34

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, January 2021– June 2021 36

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), January 2021– June 2021 37

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), January 2020– June 2021 38

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, June 2021 40

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, June 2021 40

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2021 41

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), January 2021– June 2021 42

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), January 2021– June 2021 43

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), January 2021– June 2021 45

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), January 2021– June 2021 47

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, June 2021 48

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, June 2021 49

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, June 2021 49

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 50

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, June 2021 50

5.1.1 Oncology – Deals of the Month 51

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, June 2021 52

5.2.1 Central Nervous System – Deals of the Month 53

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, June 2021 55

5.3.1 Infectious Diseases – Deals of the Month 56

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, June 2021 58

5.4.1 Cardiovascular – Deals of the Month 59

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, June 2021 61

5.5.1 Immunology – Deal of the Month 62

5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, June 2021 63

5.6.1 Metabolic– Deals of the Month 64

5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, June 2021 66

5.7.1 Gastrointestinal – Deals of the Month 67

6 Deal Summary by Geography 68

6.1 Pharmaceuticals & Healthcare, North America Deals, June 2021 68

6.1.1 North America – Deals of the Month 69

6.2 Pharmaceuticals & Healthcare, Europe, Deals, June 2021 71

6.2.1 Europe – Deals of the Month 72

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, June 2021 74

6.3.1 Asia-Pacific – Deals of the Month 75

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, June 2021 77

6.4.1 Rest of the World – Deals of the Month 78

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 80

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, January 2021 – June 2021 80

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, January 2021 – June 2021 81

8 Further Information 82

8.1 Methodology 82

8.2 About GlobalData 83

8.3 Contact Us 83

8.4 Disclosure information 83

8.5 Disclaimer 84

Table

List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, June 2021 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), June 2021 16

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 18

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, June 2021 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, January 2021 – June 2021 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, June 2021 21

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 22

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 24

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, June 2021 24

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, January 2021 – June 2021 25

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number of Deals and Deal Values (%), June 2021 27

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 28

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, December 2020– May 2021 28

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 29

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 31

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2021 – June 2021 32

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), June 2021 33

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), January 2021 – June 2021 35

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2021– June 2021 37

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), January 2021– June 2021 39

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 40

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), January 2021 – June 2021 41

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 42

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), June 2021 44

Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, January 2021– June 2021 46

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2021 – June 2021 48

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, June 2021 48

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, June 2021 49

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, June 2021 49

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 51

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 53

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 56

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021– June 2021 59

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021– June 2021 62

Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 64

Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 67

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021– June 2021 69

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 72

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 75

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 78

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), January 2021– June 2021 80

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 81

Figures

List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals (%), June 2021 15

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), June 2021 16

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, January 2021 – June 2021 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 22

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 23

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, January 2021 – June 2021 25

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number of Deals (%), June 2021 26

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), June 2021 26

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 27

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 29

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 30

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2021 – June 2021 32

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), January 2021 – June 2021 34

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2021– June 2021 36

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2021– June 2021 37

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), January 2021– June 2021 38

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 40

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2021 – June 2021 41

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 42

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), January 2021 – June 2021 43

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number of Deals, January 2021– June 2021 45

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m) January 2021– June 2021 46

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), January 2021- 2021 47

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 50

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 52

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 55

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 58

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 61

Figure 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 63

Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 66

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 68

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), January 2021– June 2021 71

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 74

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 77

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 80

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), January 2021 – June 2021 81

Frequently asked questions

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2021 in Pharmaceuticals thematic reports
Currency USD
$1,000

Can be used by individual purchaser only

$3,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Partnerships, Licensing, Investments and M&A Deals and Trends for June 2021 in Pharmaceuticals was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Partnerships, Licensing, Investments and M&A Deals and Trends for June 2021 in Pharmaceuticals in real time.

  • Access a live Partnerships, Licensing, Investments and M&A Deals and Trends for June 2021 in Pharmaceuticals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.